



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

SARS-CoV-2 Pseudoviral Particles, Omicron-BA.4 Variant

CATALOG NUMBER: SCV2-PsV-BA4, 2x 5 mL

Description

It has been known that SARS coronavirus 2 (SARS-CoV-2) uses human ACE2 as entry receptor and human proteases as entry activators. The virus surface spike protein (S) mediates SARS-CoV-2 entry into cells. To fulfill its function, SARS-CoV-2 spike binds to its human ACE2 (hACE2) receptor through its receptor-binding domain (RBD) and is proteolytically activated by human proteases.

Our **SARS-CoV-2 Omicron BA.4 Pseudoviral Particles** are replication-deficient MLV pseudotyped with the SARS-CoV-2 spike protein of the Omicron BA.4 sub-variant. They also contain the ORF for firefly luciferase as a reporter. They establish a pseudovirus cell entry assay mediated by the SARS-CoV-2 spike protein that can be conveniently measured via luciferase reporter activity. This pseudovirus assay isolates the SARS-CoV-2 viral entry from other steps of the viral infection cycle.




Figure 1. Illustration of the replication-deficient MLV particle pseudotyped with SARS-CoV-2 Spike protein

```

MFLLLTKRIMFVFLVLLPLVSSQCVNLITRQSYTNSFTRGVYYPDKVFR 50
SSVLHSTQDLFLPFFSNVTFWFAISGTNGTKRFDNPVLPFDGVIYFASTE 100
KSNIIIRGWIFGTTLDSKTQSLIVNNATNVVVKVCEQFCNDPFLDVTGH 150
KNNKSWMESEFRVYSSANNCTFEYVSQPFMLDLEKQGNFKNLREVFVKN 200
IDGYFKIYSKHTPINLGRDLPGFSALEPLVDLPIGINITRFQTLALHR 250
SYLTPGSSSGWTAGAAAYVGYLQPRTFLLKYNENGTITDAVDCALDPL 300
SETKCTLKSFVTEKGIYQTSNFRVQPTESIVRFPNITNLCPEDEVFNATR 350
FASVYAWNRRKISNCVADYSVLYNFAPFFAFKCYGVSPTKLNLDLCFNVI 400
ADSFVIRGNEVSIAPGQTGNIADYNYKLPDDFTGCVIAWNSNLDLSDKVG 450
GNYNRYRLLFRKSNLKPFFERDISTEIQAGNKPCNGVAGVNCYFPLQSYG 500
FRPTYGVGHQPYRVVLSFELLHAPATVCGPKKSTNLVKNKCVNFENGL 550
TGTGVLTESENKFLPFPQFGRDIADTTDAVRDPQTLILDITPCSFGGVS 600
VITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGNSVQTR 650
AGCLIGAEYVNNSEYCDIPIGAGICASYQTQTKSHRRARSVASQSIAYT 700
MSLGAENSVAYSNNNSIAIPTNFTISVTEILPVSMTKTSVDCCTMYICGDS 750
TECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKIYKTPPIKY 800
FGGFNFSQILPDPSPKRSFIEDLLFNKVTLADAGFIKQYDCLGDI 850
RDLICAQKFNGLTVLPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQI 900
PFAMQMAVRFNGIGVTVQNVLYENQKLIANQFNLSAIGKIQDLSSTASALG 950
KLQDVVNHNAQALNTLVKQLSSKFGAIVSSVLDILSRDLKVEAEVQIDRL 1000
ITGRQLSLQTVVTQQLIRAAEIRASANLAATKMECVLGQSKRVDFCGKG 1050
YHLMSFPQSAHPGVVFLHVTYVPAQEKNFHTTAPAICHDKGAHFPRREGV 1100
SNGTHWFTQRNFYEPQIITDNTFVSGNCDVVIGIVNNTVYDPLQPELD 1150
SFKEELDKYFKNHTSPDVLGDISGINASVUNIQKEIDRLNEVAKNLNES 1200
LIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCMTSCCSCSLKG 1250
CCSCGCC*
    
```

Figure 2. Protein sequence of the BA.4 spike (GISAID Accession # EPI_ISL_13410931) in SCV2-PsV-BA4 pseudoviral particles.

Applications

Our Pseudovirus Particles (PP) generate robust chemiluminescent signals in cell assays when coupled with our firefly luciferase assay kit (Catalog # [CA-L165](#)), useful for: 1) screening potential inhibitor to block SARS-CoV-2 entry and viral protein translation; 2) measuring the activity of and screening for neutralizing antibody against SARS-CoV-2-Omicron BA.4 (refer to [the Neutralization Assay Application Note](#)).

Features

- **Robust:** Excellent signal to noise (basal) ratio
- **Easy to use:** Amenable to HTS format (96-well, 384-well and 1536-well format)

Contents

10 ml (2 tubes, 5 mL/tube), for 2 multi-well plates; PP per mL ~ 1.0E+07

Storage

Upon receiving it, store at -70 °C right away. Thaw* before immediate use.

***Note: read the instruction for thawing in the following protocol carefully. Do not aliquot and refreeze.**

Shelf Life:

Six months from the date of shipping when stored at -70 °C

ASSAY PROTOCOL

Note: requires a luciferase assay reagent (Catalog # [CA-L165](#)).

Cell Infection:

1. Count HEK293-ACE2 cells (Catalog # [CL-hACE2-001](#)) to be infected and seed ~20K cells per well into 96-well plates (50 µl per well) DMEM with 10% HyClone™ FetalClone™ II Serum (no antibiotics) or 5K cells per well into 384-well plates (15 µl per well).
2. Culture cells overnight to make sure the cells stably adhere to the plates.
3. On the 2nd day, remove media, add 50 µl SARS-CoV-2 Omicron BA.4 Pseudoviral Particles* into each well (12.5 µl for 384-well plate). Spin at 700 rpm for 15 min at 4°C.

***Note: thaw the pseudoviral particles quickly in the room temperature water (< 30 minutes, do not shake) and use right away. Discard the unused portion (do not re-freeze or leave it on ice for later use).**

4. Incubate for 2 hrs at 37 °C.
5. Add 50 µl DMEM with 10% FC into each well (12.5 µl for 384-well plates).
6. Incubate for 42 hrs at 37 °C.

Measurement of Luciferase Activity in Infected cells

1. Do not remove supernatant. Add 100 µl eEnzyme’s luciferase assay reagent (25 µl for 384-well plates).
2. Read in a luminescence plate reader and record the data.

Data Analysis




Figure 3. Pseudoviral Particle (PP) Infection assays (SARS-CoV-2 Omicron BA.4 variant pseudoviral particles on HEK293-ACE2 cells) (Luminescence plate reader: BioTek Synergy 2)

Legends:

SARS-2-BA4-PP: SARS-CoV-2 Omicron BA.4 variant MLV pseudoviral particles, SCV2-PsV-BA4

(-): MLV control (w/o envelope spike protein) (Catalog # [PsV-001](#))